Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. May 27, 2024; 16(5): 860-862
Published online May 27, 2024. doi: 10.4254/wjh.v16.i5.860
Published online May 27, 2024. doi: 10.4254/wjh.v16.i5.860
Gestational diabetes mellitus may predispose to metabolic dysfunction-associated steatotic liver disease
Charalampos Milionis, Eftychia Koukkou, Department of Endocrinology, Diabetes and Metabolism, Elena Venizelou General Hospital, Athens 11521, Greece
Ioannis Ilias, Department of Endocrinology, Hippocration General Hospital, Athens GR-11527, Greece
Author contributions: Milionis C, Ilias I, and Koukkou E conceived and designed this work. Milionis C, Ilias I, and Koukkou E researched the literature; Milionis C, Ilias I, and Koukkou E wrote the manuscript; Milionis C, Ilias I, and Koukkou E have read and approved the final manuscript.
Conflict-of-interest statement: All authors have no conflicts of interest to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ioannis Ilias, MD, PhD, Director, Department of Endocrinology, Hippocration General Hospital, 63, Evrou Street, Athens GR-11527, Greece.
Received: January 29, 2024
Revised: February 29, 2024
Accepted: April 9, 2024
Published online: May 27, 2024
Processing time: 113 Days and 14.9 Hours
Revised: February 29, 2024
Accepted: April 9, 2024
Published online: May 27, 2024
Processing time: 113 Days and 14.9 Hours
Core Tip
Core Tip: A recent large-scale study inculpates gestational diabetes mellitus (GDM) as a novel risk factor for metabolic dysfunction-associated steatotic liver disease (MASLD). The impact of GDM on disease progression is exerted throughout life. Early screening and management strategies are crucial in mitigating MASLD progression and preventing adverse cardiovascular events in affected individuals.